WT Cheng, CW Lam, CH Ko

Abstract

Folinic acid is known to affect synthesis and catabolism of neurotransmitter, but its role in movement disorder is unknown. In our case study, we found significant clinical improvement of refractory chorea in a girl with GNAO1 variant after therapeutic trial of folinic acid. This novel therapy not only provides safe pharmacological means for potentially lethal and debilitating condition, but spares the need of surgery for control of involuntary movement. The benefit of folinic acid was found not secondary to the cerebral folate deficiency. Future study will be required to delineate the mechanism of folinic acid in controlling movement disorders.